

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if		uninvolved
Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		uninvolved
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		uninvolved
Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		uninvolved
Animal observed in or captured from the field: Provide species, sex and age where possible		uninvolved
Model organisms: Provide Accession number in repository (where relevant) OR RRID		uninvolved
Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		uninvolved
Microbes: provide species and strain, unique accession number if available, and source		uninvolved
Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		uninvolved
Provide statement confirming informed consent obtained from study participants.		uninvolved
Report on age and sex for all study participants.		uninvolved

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.		uninvolved
Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		uninvolved
Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been done, or if they were not carried out.		uninvolved
Sample size determination		uninvolved
Randomisation		uninvolved
Blinding		uninvolved
Inclusion/exclusion criteria		uninvolved
Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory		uninvolved
Define whether data describe technical or biological replicates		uninvolved
Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		uninvolved
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		uninvolved
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		uninvolved
Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		uninvolved

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		
Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	The statistical analysis and visualization of this study were obtained by R 3.6.1 with the SVA, ConsensusClusterPlus, gsva, princomp, limma, pRRophetic packages. The statistical methods are based on the recommended methods built into the respective software packages for different data types. Kaplan-Meier survival curves were drawn and compared between subgroups using the survival package. All tests were bilateral, and statistical significance was defined as $p < 0.05$.	NO
Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		uninvolved
If data are publicly available, provide accession number in repository or DOI or URL.	Section: <i>Data acquisition</i> TCGA website (https://portal.gdc.cancer.gov/) CGGA website (http://www.cgga.org.cn/)	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Section: <i>Data acquisition</i> TCGA website (https://portal.gdc.cancer.gov/) CGGA website (http://www.cgga.org.cn/)	
Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	Section: <i>Statistical Analysis</i>	
If code is publicly available, provide accession number in repository, or DOI or URL.	Section: <i>Statistical Analysis</i>	

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: <https://dx.doi.org/10.21037/atm-21-3139>